$6.58
1.54% yesterday
Nasdaq, May 20, 10:15 pm CET
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Day One Biopharmaceuticals Inc Target price 2025 - Analyst rating & recommendation

Day One Biopharmaceuticals Inc Classifications & Recommendation:

Buy
89%
Hold
11%

Day One Biopharmaceuticals Inc Price Target

Target Price $28.00
Price $6.58
Potential
Number of Estimates 8
8 Analysts have issued a price target Day One Biopharmaceuticals Inc 2026 . The average Day One Biopharmaceuticals Inc target price is $28.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend Day One Biopharmaceuticals Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Day One Biopharmaceuticals Inc stock has an average upside potential 2026 of . Most analysts recommend the Day One Biopharmaceuticals Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 131.16 151.69
15.66%
EBITDA Margin -164.10% -112.06%
31.71%
Net Margin -78.82% -92.16%
16.93%

9 Analysts have issued a sales forecast Day One Biopharmaceuticals Inc 2025 . The average Day One Biopharmaceuticals Inc sales estimate is

$152m
Unlock
. This is
6.32% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$161m 0.57%
Unlock
, the lowest is
$139m 14.22%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $131m
2025
$152m 15.66%
Unlock
2026
$237m 56.35%
Unlock
2027
$374m 57.60%
Unlock
2028
$476m 27.29%
Unlock
2029
$658m 38.36%
Unlock

3 Analysts have issued an Day One Biopharmaceuticals Inc EBITDA forecast 2025. The average Day One Biopharmaceuticals Inc EBITDA estimate is

$-170m
Unlock
. This is
9.94% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-151m 19.83%
Unlock
, the lowest is
$-195m 3.06%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-215m 4.65%
2025
$-170m 21.02%
Unlock
2026
$-119m 30.16%
Unlock
2027
$4.0m 103.35%
Unlock

EBITDA Margin

2024 -164.10%
2025
-112.06% 31.71%
Unlock
2026
-50.05% 55.34%
Unlock
2027
1.07% 102.14%
Unlock

9 Day One Biopharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Day One Biopharmaceuticals Inc net profit estimate is

$-140m
Unlock
. This is
105.88% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-117m 72.27%
Unlock
, the lowest is
$-156m 129.85%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-103m 56.96%
2025
$-140m 35.23%
Unlock
2026
$-84.8m 39.36%
Unlock
2027
$18.7m 122.04%
Unlock
2028
$100m 435.65%
Unlock
2029
$193m 92.95%
Unlock

Net Margin

2024 -78.82%
2025
-92.16% 16.93%
Unlock
2026
-35.74% 61.22%
Unlock
2027
5.00% 113.99%
Unlock
2028
21.03% 320.60%
Unlock
2029
29.33% 39.47%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.02 -1.38
56.96% 35.29%
P/E negative
EV/Sales 1.30

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast for earnings per share. The average Day One Biopharmaceuticals Inc EPS is

$-1.38
Unlock
. This is
105.97% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.15 71.64%
Unlock
, the lowest is
$-1.54 129.85%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.02 56.96%
2025
$-1.38 35.29%
Unlock
2026
$-0.84 39.13%
Unlock
2027
$0.18 121.43%
Unlock
2028
$0.99 450.00%
Unlock
2029
$1.91 92.93%
Unlock

P/E ratio

Current -9.84 51.85%
2025
-4.77 51.52%
Unlock
2026
-7.87 64.99%
Unlock
2027
35.70 553.62%
Unlock
2028
6.66 81.34%
Unlock
2029
3.45 48.20%
Unlock

Based on analysts' sales estimates for 2025, the Day One Biopharmaceuticals Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.22
2025
1.30 6.37%
Unlock
2026
0.83 36.04%
Unlock
2027
0.53 36.54%
Unlock
2028
0.41 21.44%
Unlock
2029
0.30 27.72%
Unlock

P/S ratio

Current
2025
4.40 6.74%
Unlock
2026
2.81 36.04%
Unlock
2027
1.78 36.55%
Unlock
2028
1.40 21.44%
Unlock
2029
1.01 27.73%
Unlock

Current Day One Biopharmaceuticals Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked May 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 03 2025
Goldman Sachs
Locked
Locked
Locked Mar 25 2025
JP Morgan
Locked
Locked
Locked Mar 05 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 26 2025
Needham
Locked
Locked
Locked Feb 26 2025
Wedbush
Locked
Locked
Locked Feb 26 2025
Analyst Rating Date
Locked
Needham:
Locked
Locked
May 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 03 2025
Locked
Goldman Sachs:
Locked
Locked
Mar 25 2025
Locked
JP Morgan:
Locked
Locked
Mar 05 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 26 2025
Locked
Needham:
Locked
Locked
Feb 26 2025
Locked
Wedbush:
Locked
Locked
Feb 26 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today